Wolverine Blend
Wolverine Stack
The Wolverine Blend is the most widely used pre-mixed repair peptide combination, pairing BPC-157 and TB-500 in a single vial. Named for its regenerative parallels, this blend combines two peptides with complementary but non-overlapping repair mechanisms: BPC-157 drives local tissue repair through angiogenesis and nitric oxide modulation, while TB-500 promotes systemic repair through actin polymerization and cell migration. Together they cover the full healing cascade from inflammation reduction to structural remodeling.
Starting dose. 250mcg BPC + 250mcg TB per injection
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
The Wolverine Blend combines two complementary repair mechanisms that together address the full tissue healing cascade:
BPC-157 Component: Activates local repair pathways by upregulating VEGF (vascular endothelial growth factor) for new blood vessel formation at injury sites, modulating the nitric oxide system for improved blood flow and cellular signaling, increasing GH receptor expression to amplify growth hormone effects on target tissue, and activating the FAK-paxillin pathway to drive cell migration to damaged areas. BPC-157 also promotes organized collagen deposition over scar tissue formation.
TB-500 Component: Drives systemic repair through regulation of actin polymerization and cytoskeletal dynamics. By controlling the balance between G-actin monomers and F-actin filaments, TB-500 enables repair cells (fibroblasts, endothelial cells, stem cells) to migrate effectively to injury sites throughout the body. TB-500 also suppresses NF-kB inflammatory signaling and promotes angiogenesis through distinct pathways from BPC-157.
Synergy: BPC-157's local angiogenesis and NO modulation create the vascular infrastructure, while TB-500's actin-driven cell migration delivers repair cells through that infrastructure. BPC-157's GH receptor upregulation amplifies the effects of both endogenous GH and any GH-releasing peptides used concurrently. The combination consistently outperforms either peptide used alone in anecdotal reports.
What to expect
Days 1-7: Reduced inflammation and pain from both BPC-157 (local NO modulation) and TB-500 (NF-kB suppression). Acute injuries may show noticeable improvement within 48-72 hours. Mild warmth or redness at injection site is normal and resolves in minutes.
Weeks 2-4: Significant healing progress. BPC-157 angiogenesis creating new blood vessel networks at injury sites while TB-500 cell migration delivers repair cells. Chronic injuries begin responding. Tendon and ligament pain markedly reduced. This is the period of most dramatic improvement for most users.
Weeks 4-12: Structural repair consolidation. Collagen remodeling from BPC-157 continues. TB-500 anti-fibrotic effects reduce scar tissue formation. Chronic issues that developed over months may need this full timeframe. Consider cycling off after 8-12 weeks with a 4-week break.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Exact-molecule abstract evidence. ESearch was run and 8 source-candidate PMIDs were EFetch-checked; no usable exact-molecule abstract sentence was found for the blend.
Dose/route: 250mcg BPC + 250mcg TB per injection; Subcutaneous (SubQ) injection near injury site or abdomen; Daily. No selected live abstract sentence verified this complete regimen.
Mechanism as written in source JSON. No selected live abstract sentence verified the complete mechanism at the card formulation/route and relevant population/model.
Primary safety claim as written in source JSON. No selected live abstract sentence verified the complete safety claim for this exact formulation and route.
The honest take
Wolverine-like regeneration of damaged tissue
Marketing hyperbole. Both peptides accelerate normal healing processes but do not enable regeneration of lost tissue. Animal data shows faster repair, not regrowth of structures.
Mechanistically plausible - they target different repair pathways (angiogenesis vs cell migration). However, no controlled human or animal study has directly compared the combination to either peptide alone.
Supported by toxicology data. Multiple animal studies have failed to establish an LD50, indicating a very wide safety margin. This does not guarantee safety at all doses in humans.
Interactions & stacking
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Documented together
Keep separate
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
Side effects & safety
Commonly reported
- Mild injection site redness or warmth (resolves in minutes)
- Occasional lightheadedness immediately post-injection
- Temporary GI changes during gut healing phase
- Mild fatigue in first few days as repair processes activate
Less common & notes
- Rarely reported: headache, transient nausea, increased dream vividness.
- Both BPC-157 and TB-500 have exceptionally favorable safety profiles in animal studies.
- BPC-157 has no established LD50 (no lethal dose found).
- However, long-term human safety data for the combination does not exist.
Pharmacokinetics
BPC-157: ~2 min (rapid distribution); TB-500: ~2-3 hours (systemic)
BPC-157: minutes (local effects); TB-500: 1-2 hours
BPC-157: ~20 hours (activity); TB-500: ~12-16 hours
Both ~100% SubQ; BPC-157 ~50% oral
BPC-157: 12-24 hours (VEGF/eNOS modulation persists beyond plasma clearance); TB-500: 24-48 hours (actin effects persist due to longer half-life)
Enzymatic degradation by peptidases. BPC-157 is acid-stable in GI tract. TB-500 cleared systemically.
Storage. Reconstitute with bacteriostatic water. Store refrigerated at 2-8 degrees C. Both BPC-157 and TB-500 are reasonably stable peptides. Shelf life approximately 28 days after reconstitution. Do not freeze after reconstitution. Protect from prolonged light exposure. Discard if cloudy or particulate matter visible.
Regulatory status
Not FDA-approved. Available through compounding pharmacies with prescription in some jurisdictions and through research chemical suppliers. Both BPC-157 and TB-500 are classified as research peptides. BPC-157 has been granted FDA Orphan Drug Designation for short bowel syndrome. All current human use of this blend is experimental and off-label.
Put it to work
Calculate, log & track
Open Wolverine Blend straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Wolverine Blend in the app →Go deeper
The guide & community
The complete Wolverine Blend walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗